<DOC>
	<DOCNO>NCT00212472</DOCNO>
	<brief_summary>The purpose study see low-dose arm high dose-arm immune tolerance effective eliminating inhibitor patient hemophilia A .</brief_summary>
	<brief_title>International Immune Tolerance Study</brief_title>
	<detailed_description>Subjects randomize low-dose high-dose immune tolerance regimen study compare success rate , time achieve tolerance , complication cost regimens.It also aim identify predictor successful immune tolerance .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( FVIII level &lt; 1 % ) . A maximum historical inhibitor titer 5 BU 200 BU must confirm prior beginning ITI . The inhibitor titer &lt; 10 BU start ITI , confirm . The inhibitor must present &lt; 24 month ITI begin . Maximum age 7 start ITI . Willingness comply protocol . Moderate mild hemophilia A ( FVIII level &gt; 1 % ) . Spontaneous disappearance inhibitor prior ITI . Historical maximum inhibitor titer &lt; 5 BU &gt; 200 BU start ITI . Inhibitor titer &gt; 10 BU start ITI . Inhibitor present 24 month start ITI . Systemic immunomodulatory drug therapy immune tolerance e.g . corticosteroid ( &lt; 5 day every 2 month maximum dose 2 mg/kg 60 mg/day ) , azathioprine , cyclophosphamide , highdose immunoglobulin use protein A column plasmapheresis . Age &gt; 7 year start ITI . Inability unwillingness comply protocol . Previous attempt ITI .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>